Letter: BSE inquiry
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Sir: Dr Stephen Dealler is entitled to his views on the inadequacy or otherwise of the consultation process involved in the BSE problem, but he is quite wrong to state that "pharmaceutical companies were advised not to research methods of treatment".
Decisions by pharmaceutical companies to seek to develop new therapeutic approaches to any disease are a strategic matter for them alone. No external body advises companies not to carry out research.
The pharmaceutical industry and the Medical Research Council took the lead earlier this year to meet and discuss how therapeutic advances made by the industry in other related fields, such as Alzheimer's disease, could be adopted.
Dr Jeff Kipling
Director of Science and Technology
The Association of the British Pharmaceutical Industry
London SW1
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments